Cargando…
Zimbabwe’s national third-line antiretroviral therapy program: Cohort description and treatment outcomes
BACKGROUND: In 2015, Zimbabwe introduced third-line antiretroviral therapy (ART) through four designated treatment centers; three government clinics in Harare and Bulawayo, and Newlands Clinic (NC), operated by a private voluntary organization in Harare. We describe characteristics of patients recei...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7051055/ https://www.ncbi.nlm.nih.gov/pubmed/32119663 http://dx.doi.org/10.1371/journal.pone.0228601 |
_version_ | 1783502703388786688 |
---|---|
author | Chimbetete, Cleophas Shamu, Tinei Keiser, Olivia |
author_facet | Chimbetete, Cleophas Shamu, Tinei Keiser, Olivia |
author_sort | Chimbetete, Cleophas |
collection | PubMed |
description | BACKGROUND: In 2015, Zimbabwe introduced third-line antiretroviral therapy (ART) through four designated treatment centers; three government clinics in Harare and Bulawayo, and Newlands Clinic (NC), operated by a private voluntary organization in Harare. We describe characteristics of patients receiving third line ART and analyzed treatment outcomes in this national programme as of 31 December 2018. METHODS: We described the population using proportions for categorical variables, and medians and interquartile ranges for continuous variables. Patients from NC, where data were more complete, were followed from the date of starting third-line ART until death, transfer, loss to follow up or 31 December 2018. RESULTS: A total of 209 patients had ever received third-line ART: 124 at NC and 85 from the three government clinics. HIV genotype results were available for 89 (72%) patients at NC and fourteen (16.5%) patients in the government clinics. Median duration of third line ART (years) in the government clinics was 2.3 (IQR:0.6–3.4), 1.3 (IQR: 0.7–1.7) and 1 (0.6–1.9). Of the 67 patients who received third line ART in the government clinics for at least six months, 53 (79%) had most recent viral load (VL) < 1000 copies/ml. Data on other treatment outcomes from government clinics were incomplete. From NC: a total of 109 (88%) patients were still in care, 13 (10.5%) had died and 2 (1.5%) were transferred. Median duration of third-line ART was 1.4 years (IQR: 0.6–2.8). Among the 111 NC patients who had received third-line ART for at least 6 months, 83 (75%) had a VL <50 copies/ml and 106 (95.5%) had a VL <1000 copies/ml. CONCLUSION: Our findings demonstrate that, with comprehensive care, patients failing second-line ART can achieve high rates of virological suppression on third-line regimens. There is need to decentralize the provision of third-line ART in Zimbabwe. More needs to be done to improve completeness of data in the government clinics. |
format | Online Article Text |
id | pubmed-7051055 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-70510552020-03-12 Zimbabwe’s national third-line antiretroviral therapy program: Cohort description and treatment outcomes Chimbetete, Cleophas Shamu, Tinei Keiser, Olivia PLoS One Research Article BACKGROUND: In 2015, Zimbabwe introduced third-line antiretroviral therapy (ART) through four designated treatment centers; three government clinics in Harare and Bulawayo, and Newlands Clinic (NC), operated by a private voluntary organization in Harare. We describe characteristics of patients receiving third line ART and analyzed treatment outcomes in this national programme as of 31 December 2018. METHODS: We described the population using proportions for categorical variables, and medians and interquartile ranges for continuous variables. Patients from NC, where data were more complete, were followed from the date of starting third-line ART until death, transfer, loss to follow up or 31 December 2018. RESULTS: A total of 209 patients had ever received third-line ART: 124 at NC and 85 from the three government clinics. HIV genotype results were available for 89 (72%) patients at NC and fourteen (16.5%) patients in the government clinics. Median duration of third line ART (years) in the government clinics was 2.3 (IQR:0.6–3.4), 1.3 (IQR: 0.7–1.7) and 1 (0.6–1.9). Of the 67 patients who received third line ART in the government clinics for at least six months, 53 (79%) had most recent viral load (VL) < 1000 copies/ml. Data on other treatment outcomes from government clinics were incomplete. From NC: a total of 109 (88%) patients were still in care, 13 (10.5%) had died and 2 (1.5%) were transferred. Median duration of third-line ART was 1.4 years (IQR: 0.6–2.8). Among the 111 NC patients who had received third-line ART for at least 6 months, 83 (75%) had a VL <50 copies/ml and 106 (95.5%) had a VL <1000 copies/ml. CONCLUSION: Our findings demonstrate that, with comprehensive care, patients failing second-line ART can achieve high rates of virological suppression on third-line regimens. There is need to decentralize the provision of third-line ART in Zimbabwe. More needs to be done to improve completeness of data in the government clinics. Public Library of Science 2020-03-02 /pmc/articles/PMC7051055/ /pubmed/32119663 http://dx.doi.org/10.1371/journal.pone.0228601 Text en © 2020 Chimbetete et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Article Chimbetete, Cleophas Shamu, Tinei Keiser, Olivia Zimbabwe’s national third-line antiretroviral therapy program: Cohort description and treatment outcomes |
title | Zimbabwe’s national third-line antiretroviral therapy program: Cohort description and treatment outcomes |
title_full | Zimbabwe’s national third-line antiretroviral therapy program: Cohort description and treatment outcomes |
title_fullStr | Zimbabwe’s national third-line antiretroviral therapy program: Cohort description and treatment outcomes |
title_full_unstemmed | Zimbabwe’s national third-line antiretroviral therapy program: Cohort description and treatment outcomes |
title_short | Zimbabwe’s national third-line antiretroviral therapy program: Cohort description and treatment outcomes |
title_sort | zimbabwe’s national third-line antiretroviral therapy program: cohort description and treatment outcomes |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7051055/ https://www.ncbi.nlm.nih.gov/pubmed/32119663 http://dx.doi.org/10.1371/journal.pone.0228601 |
work_keys_str_mv | AT chimbetetecleophas zimbabwesnationalthirdlineantiretroviraltherapyprogramcohortdescriptionandtreatmentoutcomes AT shamutinei zimbabwesnationalthirdlineantiretroviraltherapyprogramcohortdescriptionandtreatmentoutcomes AT keiserolivia zimbabwesnationalthirdlineantiretroviraltherapyprogramcohortdescriptionandtreatmentoutcomes |